vs
HomeTrust Bancshares, Inc.（HTB）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
HomeTrust Bancshares, Inc.的季度营收约是ARS Pharmaceuticals, Inc.的1.9倍（$53.6M vs $28.1M），HomeTrust Bancshares, Inc.同比增速更快（3.7% vs -67.6%）
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
HTB vs SPRY — 直观对比
营收规模更大
HTB
是对方的1.9倍
$28.1M
营收增速更快
HTB
高出71.2%
-67.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $28.1M |
| 净利润 | — | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | 37.0% | -147.6% |
| 净利率 | — | -147.1% |
| 营收同比 | 3.7% | -67.6% |
| 净利润同比 | — | -182.8% |
| 每股收益（稀释后） | $0.93 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBSPRY
| Q4 25 | $53.6M | $28.1M | ||
| Q3 25 | $54.1M | $32.5M | ||
| Q2 25 | $54.4M | $15.7M | ||
| Q1 25 | $50.9M | $8.0M | ||
| Q4 24 | $51.7M | $86.6M | ||
| Q3 24 | $50.6M | $2.1M | ||
| Q2 24 | $50.6M | $500.0K | ||
| Q1 24 | $50.0M | $0 |
净利润HTBSPRY
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $16.5M | $-51.2M | ||
| Q2 25 | $17.2M | $-44.9M | ||
| Q1 25 | $14.5M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $13.1M | $-19.1M | ||
| Q2 24 | $12.4M | $-12.5M | ||
| Q1 24 | $15.1M | $-10.3M |
营业利润率HTBSPRY
| Q4 25 | 37.0% | -147.6% | ||
| Q3 25 | 38.5% | -163.7% | ||
| Q2 25 | 40.1% | -302.9% | ||
| Q1 25 | 36.2% | -466.3% | ||
| Q4 24 | 35.4% | 54.5% | ||
| Q3 24 | 33.2% | -1051.6% | ||
| Q2 24 | 31.3% | -3068.0% | ||
| Q1 24 | 38.0% | — |
净利率HTBSPRY
| Q4 25 | — | -147.1% | ||
| Q3 25 | 30.5% | -157.4% | ||
| Q2 25 | 31.6% | -285.6% | ||
| Q1 25 | 28.5% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 25.9% | -925.0% | ||
| Q2 24 | 24.6% | -2503.2% | ||
| Q1 24 | 30.1% | — |
每股收益（稀释后）HTBSPRY
| Q4 25 | $0.93 | $-0.41 | ||
| Q3 25 | $0.95 | $-0.52 | ||
| Q2 25 | $1.00 | $-0.46 | ||
| Q1 25 | $0.84 | $-0.35 | ||
| Q4 24 | $0.83 | $0.52 | ||
| Q3 24 | $0.76 | $-0.20 | ||
| Q2 24 | $0.73 | $-0.13 | ||
| Q1 24 | $0.88 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.7M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $600.7M | $114.3M |
| 总资产 | $4.5B | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资HTBSPRY
| Q4 25 | $324.7M | $245.0M | ||
| Q3 25 | $315.8M | $288.2M | ||
| Q2 25 | $297.2M | $240.1M | ||
| Q1 25 | $299.8M | $275.7M | ||
| Q4 24 | $279.2M | $314.0M | ||
| Q3 24 | $293.5M | $204.6M | ||
| Q2 24 | $294.2M | $218.7M | ||
| Q1 24 | $380.5M | $223.6M |
总债务HTBSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HTBSPRY
| Q4 25 | $600.7M | $114.3M | ||
| Q3 25 | $595.8M | $147.7M | ||
| Q2 25 | $579.3M | $192.3M | ||
| Q1 25 | $565.4M | $229.0M | ||
| Q4 24 | $551.8M | $256.8M | ||
| Q3 24 | $540.0M | $201.0M | ||
| Q2 24 | $523.6M | $215.2M | ||
| Q1 24 | $513.2M | $223.9M |
总资产HTBSPRY
| Q4 25 | $4.5B | $327.7M | ||
| Q3 25 | $4.6B | $372.8M | ||
| Q2 25 | $4.6B | $313.5M | ||
| Q1 25 | $4.6B | $327.3M | ||
| Q4 24 | $4.6B | $351.2M | ||
| Q3 24 | $4.6B | $217.6M | ||
| Q2 24 | $4.7B | $222.0M | ||
| Q1 24 | $4.7B | $227.6M |
负债/权益比HTBSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $45.3M | — |
| 自由现金流率自由现金流/营收 | 84.5% | — |
| 资本支出强度资本支出/营收 | 7.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $93.8M | — |
8季度趋势，按日历期对齐
经营现金流HTBSPRY
| Q4 25 | $49.5M | $-43.5M | ||
| Q3 25 | $-11.3M | $-47.0M | ||
| Q2 25 | $-8.8M | $-39.6M | ||
| Q1 25 | $71.7M | $-40.7M | ||
| Q4 24 | $45.4M | $42.0M | ||
| Q3 24 | $43.8M | $-14.5M | ||
| Q2 24 | $5.9M | $-7.3M | ||
| Q1 24 | $-9.0M | $-6.7M |
自由现金流HTBSPRY
| Q4 25 | $45.3M | — | ||
| Q3 25 | $-12.0M | $-47.2M | ||
| Q2 25 | $-10.2M | $-39.6M | ||
| Q1 25 | $70.7M | $-40.8M | ||
| Q4 24 | $42.4M | $41.7M | ||
| Q3 24 | $43.1M | $-14.6M | ||
| Q2 24 | $5.7M | $-7.3M | ||
| Q1 24 | $-9.6M | $-6.8M |
自由现金流率HTBSPRY
| Q4 25 | 84.5% | — | ||
| Q3 25 | -22.2% | -145.4% | ||
| Q2 25 | -18.7% | -252.2% | ||
| Q1 25 | 138.7% | -512.1% | ||
| Q4 24 | 82.0% | 48.2% | ||
| Q3 24 | 85.1% | -706.3% | ||
| Q2 24 | 11.2% | -1463.4% | ||
| Q1 24 | -19.2% | — |
资本支出强度HTBSPRY
| Q4 25 | 7.8% | 0.0% | ||
| Q3 25 | 1.4% | 0.6% | ||
| Q2 25 | 2.5% | 0.3% | ||
| Q1 25 | 2.0% | 1.1% | ||
| Q4 24 | 5.9% | 0.3% | ||
| Q3 24 | 1.3% | 6.8% | ||
| Q2 24 | 0.5% | 7.6% | ||
| Q1 24 | 1.1% | — |
现金转化率HTBSPRY
| Q4 25 | — | — | ||
| Q3 25 | -0.68× | — | ||
| Q2 25 | -0.51× | — | ||
| Q1 25 | 4.93× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 3.34× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | -0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTB
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
